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ABSTRACT
Objective: Telomerase enzyme which is expressed in detectable levels and its mechanism was that it increases the length when it binds to telomeres. 
This eventually leads to extension of lifespan of cells and also makes an attractive target for cancer therapy. Perylene diimides bind to telomerase 
with duplex genomic DNA, and these G-quadruplex ligands are of responsible for binding affinity with respective proteins. Based on the IC50 values of 
perylene diimides, QSAR has been studied out and the results are elaborated in preliminary research works. From the results of QSAR, the selected 
perylene ligands are selected for docking choosing telomerase as a target/protein. From the results of in silico studies, new compounds are designed 
and synthesized accordingly. Now, the objective of the study was to dock the final synthesized compounds with the telomerase protein to study 
regarding the pKi value using G-quadruplex ligand database (G4LDB). The docked results are visualized using Discovery Studio Visualizer 4.1. The 
results are compared with the standard N,N’-bis-(2-(1-piperidino)ethyl)-3,4,9,10-perylene tetracarboxylic acid diimide (PIPER) drug and these 
compounds will be effective for anticancer therapy.
Methods: The study was to investigate the docking results of synthesized perylene compounds with the results from G4LDB and visualized by 
Discovery Studio 4.1 Visualizer. The telomerase proteins selected for the study were extracted from Protein Data Bank, and the proteins selected for 
the study are 3SC8 and 3CE5. Among the compounds (R1, R2, R3, and R4) screened in G-Quadruplex Ligand Database, compound R3 shows better 
binding affinity with good pKi value as well the interactions with the protein and ligand show better affinity with the targets and these are compared 
with the standard drug PIPER drug.
Results: Compound R3 possesses the best binding affinity with the target 3CE5 and 3SC8 which shows that the compound will be effective for 
anticancer therapy.
Keywords: AutoDock, G-Quadruplex ligand database, Docking, Perylene derivatives.
INTRODUCTION
G-Quadruplex stabilization promotes apoptosis
G-Quartets are square planar arrangements of four guanine 
bases [1-5] and these are stable stacks in macromolecule 
sequences [6-8]. These structures are G-quadruplexes which 
contain purine tetrads [9]. G-quadruplexes area unit four-stranded 
guanine-wealthy DNA structures present at the telomeric ends [10]. 
G-Quadruplex stabilization leads to inhibition of the telomerase activity, 
which induces the apoptosis [11,12]. The compounds such as PDI, NDI, 
and hexazole are the possible intercalators acting on the G-quartet 
structure and stabilize it. For eg: Cationic porphyrin, Quindoline, 
Berberine and trisubstitutes iso-alloxazines have been incontestable to 
interfere with the oncogenic transcription invitro [13-15].
The compounds are docked using G-quadruplex ligand database 
(G4LDB). The G4LDB online docking proceeds as the compounds are 
converted from two dimensional to three dimensional. This module 
incorporated 28 docking models of G-quadruplexes. Once ligand has 
been designed, job for docking has been submitted [16-18].
METHODS
G4LDB
The four synthesized perylene compounds are docked using G-Quadruplex 
Ligand Database. The perylene compounds are tabulated in Table 1.
In step one, perylene compounds are drawn and the structures are 
converted to simplified molecular-input line-entry system (SMILES) format 
using online SMILES translator. In step two, the target (3CE5 and 3SC8) was 
chosen and the compounds in SMILE format were given for computation. 
The process will take 15–20 min for completion of the docking job. The 
results are finally downloaded and the complex. Protein data bank (PDB) 
structures are visualized using Discovery Studio Visualizer 4.1.
N,N’-bis-(2-(1-piperidino)ethyl)-3,4,9,10-perylene tetracarboxylic acid 
diimide (PIPER), the standard compound, was downloaded from the 
same module and computed for docking with the two selected targets 
(3CE5 and 3SC8) to get to know about the best binding affinity toward 
the perylene and its ligands [19-21]. The targets selected for the study 
are as follows: 3CE5 and 3SC8.
The four compounds are docked with the two targets (3CE5 and 3SC8) 
and compared with the PIPER compound. The results are tabulated in 
Table 2. Among the four perylene compounds, compound R3 showed 
good pKi value when compared with the PIPER compound which shows 
that these compounds possess highest binding affinities and these 
compounds are represented in Fig. 1.
The hydrogen bond interactions with the enzyme and the ligand are 
tabulated in Tables 3 and 4.
RESULTS
Docking has been done by G-Quadruplex Ligand Database. This is 
an online database which was having inbuilt tools and performed by 
Open Babel 2.3.0 to predict the binding affinity with the targets [22]. 
The targets (3CE5 and 3SC8) for the docking are selected based on the 
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literature survey, and the four synthesized perylene compounds are 
docked. From the results, compound R3 is selected and the results of 
these compounds are visualized using Discovery Studio 4.1 Visualizer.
DISCUSSION
From the docking results of G-Quadruplex Ligand Database, compound 
R3 showed good inhibitory constant pKi value which shows the 
correlation coefficient and proves that the perylene derivatives will be 
efficient with the targets (3CE5 and 3SC8).
CONCLUSION
Based on the research work, we selected a set of perylene compounds 
by analyzing the IC50 values from literature survey. QSAR study has 
been done, and from the results, new compounds are designed from 
the QSAR equation, and hence, new compounds are designed and 
biological activity values are predicted. The designed compounds are 
screened using computational studies using selective targets from PDB, 
and a scaffold was selected for synthesis. We synthesized four perylene 
compounds and docked using G-Quadruplex Ligand Database to find 
the inhibitory value and hydrogen bond interactions with the ligand. 
The results are tabulated, and among the four perylene compounds, 
compound R3 showing more potent, the selected best compound R3 
targeting the telomerase enzyme, may be used for in vivo studies which 
will be effective for anticancer therapy.
Table 1: Structure of novel perylene diimides target molecules
S. No. Structure IUPAC name Molecular weight
R1 5,12-bis (bis (2-hydroxyethyl) amino)-2,9-dihexylanthra[2,1,9-def: 6,5,10-d’e’f ’]
diisoquinoline-1,3,8,10 (2H,9H)-tetraone
755.40
R2 14,25-Bis[bis (2-hydroxylethyl) amino]-7,18-bis (1-naphthyl)-7.18diazaheptacyclo 
[14.6.2.22,5.03,12.04,9.013,23.020,24]hexacosa1 (22),4,4 (9), 
10,13,15,20,23,25-nonaene-6,8,17,19-tetrone
853.35
R3 7,18-Bis (5-aminopentyloxy)-14,25-bis[bis (2-hydroxyethyl) amino]-7. 
18-diazaheptacyclo[14.6.2.22,5.03,12.04,9.013,23.020,24]hexacosa1 (22),4,4 (9), 
10,13,15,20,23,25-nonaene-6,8,17,19-tetrone
785.44
R4 1,7-Bis (n-diethanolamino)-N, N‑dihydroxylamine-3,4,9,10- perylenetetracarboxylic 
diimides
633.23
Table 2: Results of pKi value for the four synthesized perylene 
compounds
S. No Compound Target PDBs
3CE5 3SC8
1 R1 4.58 4.59
2 R2 2.71 2.3
3 R3 5.22 5.55
4 R4 4.45 4
5 PIPER 8.84 8.02
PIPER: N, N’-bis-(2-(1-piperidino) ethyl)-3,4,9,10-perylene tetracarboxylic acid 
diimide, PDB: Protein data bankm
Fig. 1: Results of pKi value for the four synthesized perylene 
compounds
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